In vitro study of the pharmacological efficiency of pyridinecarboxy acid derivatives

Breast cancer is one of the most common types of malignant tumors in women, ranking second in the structure of mortality after lung cancer. To assess the role of reverse transport as a mechanism of primary resistance of tumor cells to new antitumor agents, two triple-negative human breast cancer cell lines were used, one of which expresses (cell culture MDA-MB-231 (HTB-26), ATCC, USA) and the other does not express the breast cancer reverse transport protein BCRP (BT20, ATCC, USA). In this work, compounds of pyridinecarboxylic acids with laboratory codes LHT-13-19 and LHT-17-19 were studied. The presence of primary resistance to the LHT-13-17 compound and its absence to the LHT-17-19 substance, due to the reverse BCRP-mediated transport of the active substance molecules, was experimentally shown.